Procept BioRobotics sees FY23 revenue $135.9M-$136.2M, consensus $133.51M

Representing growth of approximately 81%-82% compared to the prior year period. “We are very pleased to close out 2023 with another quarter of excellent results, driven by an acceleration in monthly utilization and strong U.S. system sales,” said Reza Zadno, CEO. “As we enter 2024, we are well positioned to continue to deliver outsized revenue growth driven by outstanding real-world clinical outcomes of Aquablation Therapy, the largest and most tenured capital sales team in the company’s history, and strong surgeon interest leading to rapid adoption within urology practices.”